Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?[J]
The peptide CDMO market, valued at approximately $4.14 billion in 2025, is forecast to reach $9.84 billion by 2031 at a compound annual growth rate of 15.5%
doi: 10.1161/jaha.123.030178
For example, semaglutide could be used preoperatively to reduce surgical risk, or postoperatively to maintain weight loss and reduce the likelihood of regain [28,29,30]
For optimal results, take 2 capsules 30-60 minutes prior to exercise
When you eat, your body releases GLP-1, which sends signals to your brain, pancreas, and stomach